Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic ... [20] Nurse practitioner: A ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

A Lancet study suggests that popular weight-loss drugs could lead to muscle loss. Researchers recommend combining these ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise ... Viking noted there was no plateau in weight loss during the course of the 13 weeks. Among the patients in VENTURE, 88% ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Newly published research is the latest to suggest that semaglutide and other GLP-1 drugs can help treat people’s addiction to both opioids and alcohol. GLP-1 drugs have been a valuable treatment ...

Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a ... don't have an appetite would be smart." Of course, as Valente noted, you can also replicate ...

It found that over 12 months, 1.4% of adolescents on GLP-1 drugs had a suicide attempt or ideation, compared with 2.3% who weren’t on the medicines. There was no sign of an increase associated ...

Among the findings, the report published Monday highlights the impact of Ozempic, other GLP-1 drugs and hormones used in gender-affirming care and lays out sex- and gender-specific risks of stroke.